{"id":"W2526225966","doi":"10.1182/blood.v126.23.505.505","title":"Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Tolerability; Pembrolizumab; Dexamethasone; Internal medicine; Multiple myeloma; Oncology; Clinical endpoint; Phases of clinical research; Neutropenia; Gastroenterology; Surgery; Adverse effect; Clinical trial; Toxicity; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001606283,0.000802548,0.001616294,0.0003981854,0.000525028,0.0009089057,0.001069063,0.0008506204,0.004682809],"category_scores_gemma":[0.0005206887,0.0004161631,0.0009488468,0.0006328482,0.0005644057,0.0006925589,0.0004849205,0.002296759,0.001065407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00127854,"about_ca_system_score_gemma":0.001664391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007286071,"about_ca_topic_score_gemma":0.003114062,"domain_scores_codex":[0.9995285,0.0001822504,0.00004728823,0.00009915438,0.00005212402,0.00009067247],"domain_scores_gemma":[0.9995779,0.00005961253,0.0001026711,0.00005056192,0.00002574974,0.0001834373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6067773,0.05455102,0.01808899,0.001559171,0.001296376,0.0007435762,0.0003160271,0.002520727,0.06915695,0.0006083355,0.006382288,0.2379992],"study_design_scores_gemma":[0.4411532,0.4956463,0.03668179,0.0001397431,0.0009585102,0.001328414,0.00008710634,0.002037141,0.01046606,0.000368672,0.01107877,0.00005422965],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859024,0.003705554,0.0005537606,0.000606346,0.00009963942,0.003702188,0.001480642,0.000143197,0.003806112],"genre_scores_gemma":[0.9926082,0.0009577209,0.00139564,0.0007214425,0.00008972581,0.00144522,0.00120893,0.00001956693,0.001553693],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004682809,"threshold_uncertainty_score":0.01566553,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03552536455554776,"score_gpt":0.2941909044543848,"score_spread":0.2586655398988371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}